A5009980652- Neuroendocrine Tumor Research Advances
- Pancreatic and Hepatic Oncology Research
- Lung Cancer Research Studies
- Neuroblastoma Research and Treatments
- Cancer Genomics and Diagnostics
- Pancreatitis Pathology and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Gastrointestinal Tumor Research and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Gastrointestinal disorders and treatments
- Pituitary Gland Disorders and Treatments
- Cancer, Hypoxia, and Metabolism
- Gastric Cancer Management and Outcomes
- Intraperitoneal and Appendiceal Malignancies
- Radiomics and Machine Learning in Medical Imaging
- Renal cell carcinoma treatment
- Cancer Cells and Metastasis
- Genetic factors in colorectal cancer
- Hernia repair and management
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- Colorectal and Anal Carcinomas
- Renal and related cancers
- Pelvic and Acetabular Injuries
- PARP inhibition in cancer therapy
Hôpital Beaujon
2016-2025
Université Paris Cité
2016-2025
Inserm
2014-2025
Centre de Recherche sur l'Inflammation
2019-2025
Centre National de la Recherche Scientifique
2023-2025
Assistance Publique – Hôpitaux de Paris
2013-2024
Bicêtre Hospital
2024
University of Lausanne
2023
Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo
2023
University of Palermo
2023
Abstract This ENETS guidance paper for well‐differentiated nonfunctioning pancreatic neuroendocrine tumours (NF‐Pan‐NET) has been developed by a multidisciplinary working group, and provides up‐to‐date practical advice on the management of these tumours. Using extensive experience centres treating patients with NF‐Pan‐NEN, authors this discuss 10 troublesome questions in everyday clinical practice. Our many years field are still being verified light results new clinical, which set ways...
Two tumor (Classical/Basal) and stroma (Inactive/active) subtypes of Pancreatic adenocarcinoma (PDAC) with prognostic theragnostic implications have been described. These molecular were defined by RNAseq, a costly technique sensitive to sample quality cellularity, not used in routine practice. To allow rapid PDAC subtyping study heterogeneity, we develop PACpAInt, multi-step deep learning model. PACpAInt is trained on multicentric cohort (n = 202) validated 4 independent cohorts including...
In patients with small intestinal neuroendocrine tumors (siNETs), surgical resection of the primary tumor and associated mesenteric lymph nodes (LNs) is recommended, but not well standardized can be risky in superior vessel involvement.We aimed to evaluate correlation between length resected bowel number removed LNs, propose a preoperative morphological classification siNET-associated LNs.The records operated on for siNETs at two expert centers August 2005 November 2013 were analyzed. Two...
A mesenteric mass (MM), characterized by fibrotic reaction, is present in most small-intestinal neuroendocrine tumors (SI-NETs). <sup>177</sup>Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) has shown its efficacy patients with progressive SI-NETs. However, because of specific tissue characteristics desmoplastic MMs, we hypothesize that these lesions may be refractory to PRRT. <b>Methods:</b> From the national French Groupe d'étude des Tumeurs Endocrines database, identified an...
Management of pancreatic neuroendocrine tumors (PNETs) associated with von Hippel-Lindau disease (VHL) is challenging because the malignant potential and difficulty in predicting prognosis.Compare long-term outcome resected VHL-PNET sporadic PNET.Data all patients VHL (n = 23) operated on for nonmetastatic PNET were reviewed. Patient characteristics recurrence-free survival rates compared those PNET, matched tumor size, stage, Ki-67 index.Patients both groups had similar demographic...
BackgroundThe aim was to describe genetic, clinical and morphological features in a large, multicentre European cohort of patients with SPINK1 related pancreatitis, comparison idiopathic pancreatitis (IP).MethodsAll mutation carriers pancreatic symptoms from two French one English centers were included. Patients IP included control group. Genetic, clinical, radiological biochemical data collected.Findings209 302 the groups (median follow-up: 8.3 years (3.7–17.4) vs 5.3 (2.5–8.8)).The median...
<b><i>Background:</i></b> The combination of capecitabine (CAP) with temozolomide (TEM) chemotherapy in advanced pancreatic neuroendocrine tumors (PanNET) relies on limited evidence. We compared TEM-CAP to TEM alone patients PanNET. <b><i>Methods:</i></b> Consecutive PanNET treated or between 2004 and 2017 three expert centers were included. Progression-free survival (PFS), tolerance, tumor response, overall the two groups. Propensity-based...
Small rectal neuroendocrine tumours are good candidates for endoscopic resection provided that complete pathological (R0) is obtained and their risk of metastatic progression low. We conducted a large multicentre nationwide study to evaluate the outcomes management non-metastatic ≤2 cm diagnosed endoscopically.The medical records, findings patients with managed from January 2000-June 2018 in 16 French hospitals, were retrospectively analysed. The primary objective was describe proportion R0...
<b><i>Introduction:</i></b> Although chemotherapy combining 5-fluorouracil (5FU)-dacarbazine (DTIC) or temozolomide (TEM)-capecitabine (CAP) is extensively used in patients with neuroendocrine tumors (NET), they were never compared. We compared their tolerance and efficacy advanced NET. <b><i>Methods:</i></b> evaluated the records of consecutive pancreatic small-intestine NET who received 5FU-DTIC TEM-CAP between July 2004 December 2017 5...
<b><i>Introduction:</i></b> High-grade lung neuroendocrine tumours with carcinoid morphology have been recently reported; they may represent the thoracic counterparts of grade 3 digestive tumours. We aimed to study their genetic landscape including analysis tumoral heterogeneity. <b><i>Methods:</i></b> Eleven patients high-grade (&#x3e;20% Ki-67 and/or &#x3e;10 mitoses) a were included. analysed copy number variations, somatic...
Pancreatic neuroendocrine tumours (PanNETs) have intra-tumour heterogeneity, notably regarding the Ki-67 index, which is a major prognostic factor. The temporal evolution of PanNET biology poorly known. We aimed to study impact and other molecular markers (MEN1, ATRX/DAXX, PDX1/ARX) in PanNETs. retrospectively studied 109 patients with sporadic PanNETs serial tumour samples (n=286), on we measured index expression markers. Variables associated shorter overall survival [OS] increase over time...